Stryker Co. (NYSE:SYK) Director Sells $68,972,963.40 in Stock

Stryker Co. (NYSE:SYKGet Free Report) Director Ronda E. Stryker sold 201,146 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the sale, the director now directly owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Stryker Trading Up 0.9 %

Shares of NYSE SYK opened at $342.72 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $346.59. The firm has a 50 day moving average price of $305.85 and a two-hundred day moving average price of $288.70. The stock has a market cap of $130.21 billion, a P/E ratio of 41.54, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Stryker (NYSE:SYKGet Free Report) last posted its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The company had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the prior year, the company posted $3.00 earnings per share. Stryker’s revenue for the quarter was up 11.8% compared to the same quarter last year. As a group, equities analysts forecast that Stryker Co. will post 11.87 EPS for the current year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 31st. Investors of record on Friday, December 29th were paid a dividend of $0.80 per share. The ex-dividend date was Thursday, December 28th. This is a positive change from Stryker’s previous quarterly dividend of $0.75. This represents a $3.20 annualized dividend and a yield of 0.93%. Stryker’s dividend payout ratio is currently 38.79%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SYK. Freedom Wealth Alliance LLC bought a new position in Stryker during the fourth quarter worth $26,000. Farmers & Merchants Trust Co of Chambersburg PA boosted its stake in Stryker by 203.3% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares in the last quarter. Quarry LP bought a new position in Stryker during the first quarter worth $27,000. Rise Advisors LLC boosted its stake in Stryker by 692.9% during the third quarter. Rise Advisors LLC now owns 111 shares of the medical technology company’s stock worth $30,000 after acquiring an additional 97 shares in the last quarter. Finally, Rogco LP bought a new position in shares of Stryker in the fourth quarter valued at $30,000. 76.24% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Royal Bank of Canada increased their price objective on shares of Stryker from $345.00 to $360.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 price objective for the company in a research report on Wednesday, January 31st. Wells Fargo & Company raised their target price on shares of Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 31st. Citigroup lifted their target price on shares of Stryker from $340.00 to $362.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Roth Mkm lifted their target price on shares of Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $331.52.

Check Out Our Latest Report on Stryker

About Stryker

(Get Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Further Reading

Insider Buying and Selling by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.